JP2005517672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005517672A5 JP2005517672A5 JP2003556062A JP2003556062A JP2005517672A5 JP 2005517672 A5 JP2005517672 A5 JP 2005517672A5 JP 2003556062 A JP2003556062 A JP 2003556062A JP 2003556062 A JP2003556062 A JP 2003556062A JP 2005517672 A5 JP2005517672 A5 JP 2005517672A5
- Authority
- JP
- Japan
- Prior art keywords
- urea
- methyl
- phenyl
- trifluoromethyl
- benzothiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 1,2-oxazolyl Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 150000003672 ureas Chemical class 0.000 claims 9
- 229910005965 SO 2 Inorganic materials 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- PMCOWOCKUQWYRL-UHFFFAOYSA-N 2,4-dimethylpyrimidine Chemical compound CC1=CC=NC(C)=N1 PMCOWOCKUQWYRL-UHFFFAOYSA-N 0.000 claims 2
- AGQOIYCTCOEHGR-UHFFFAOYSA-N 5-methyl-1,2-oxazole Chemical compound CC1=CC=NO1 AGQOIYCTCOEHGR-UHFFFAOYSA-N 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000014001 urinary system disease Diseases 0.000 claims 2
- 229910052727 yttrium Inorganic materials 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims 1
- JADCSAKGOJWLNK-UHFFFAOYSA-N 1-(1,3-benzothiazol-6-yl)-3-[4-chloro-3-(trifluoromethyl)phenyl]urea Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=C3SC=NC3=CC=2)=C1 JADCSAKGOJWLNK-UHFFFAOYSA-N 0.000 claims 1
- YAJQKWNCPMIGQL-UHFFFAOYSA-N 1-(1h-indol-4-yl)-3-(3-phenylphenyl)urea Chemical compound C=1C=CC=2NC=CC=2C=1NC(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 YAJQKWNCPMIGQL-UHFFFAOYSA-N 0.000 claims 1
- AUBYEGKQZULNDB-UHFFFAOYSA-N 1-(1h-indol-4-yl)-3-(4-propan-2-ylphenyl)urea Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)NC1=CC=CC2=C1C=CN2 AUBYEGKQZULNDB-UHFFFAOYSA-N 0.000 claims 1
- KOUOQFQNJRJCBF-UHFFFAOYSA-N 1-(1h-indol-4-yl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound FC(F)(F)C1=CC=CC(NC(=O)NC=2C=3C=CNC=3C=CC=2)=C1 KOUOQFQNJRJCBF-UHFFFAOYSA-N 0.000 claims 1
- SKFZWLLPTJATNS-UHFFFAOYSA-N 1-(1h-indol-4-yl)-3-naphthalen-1-ylurea Chemical compound C1=CC=C2C(NC(NC=3C=4C=CNC=4C=CC=3)=O)=CC=CC2=C1 SKFZWLLPTJATNS-UHFFFAOYSA-N 0.000 claims 1
- CSGLKTAXINXIJG-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-3-(2-methyl-1,3-benzothiazol-5-yl)urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NC1=CC=C(F)C=C1F CSGLKTAXINXIJG-UHFFFAOYSA-N 0.000 claims 1
- BCMGQANPIXFKKP-UHFFFAOYSA-N 1-(2-methyl-1,3-benzothiazol-5-yl)-3-(3-methylphenyl)urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NC1=CC=CC(C)=C1 BCMGQANPIXFKKP-UHFFFAOYSA-N 0.000 claims 1
- XPAPZRGWBKJGTG-UHFFFAOYSA-N 1-(2-methyl-1,3-benzothiazol-5-yl)-3-(4-phenoxyphenyl)urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 XPAPZRGWBKJGTG-UHFFFAOYSA-N 0.000 claims 1
- SWZFLNRAYJQQPM-UHFFFAOYSA-N 1-(2-methyl-1,3-benzothiazol-5-yl)-3-(4-propan-2-ylphenyl)urea Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)NC1=CC=C(SC(C)=N2)C2=C1 SWZFLNRAYJQQPM-UHFFFAOYSA-N 0.000 claims 1
- BQGLVNOHKZPVOD-UHFFFAOYSA-N 1-(2-methyl-1,3-benzothiazol-5-yl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 BQGLVNOHKZPVOD-UHFFFAOYSA-N 0.000 claims 1
- USBQLKQAUQKJCX-UHFFFAOYSA-N 1-(2-methyl-1,3-benzothiazol-5-yl)-3-naphthalen-1-ylurea Chemical compound C1=CC=C2C(NC(=O)NC=3C=C4N=C(SC4=CC=3)C)=CC=CC2=C1 USBQLKQAUQKJCX-UHFFFAOYSA-N 0.000 claims 1
- RAUVGBSGKKWNCA-UHFFFAOYSA-N 1-(2-methyl-1,3-benzothiazol-5-yl)-3-naphthalen-2-ylurea Chemical compound C1=CC=CC2=CC(NC(=O)NC=3C=C4N=C(SC4=CC=3)C)=CC=C21 RAUVGBSGKKWNCA-UHFFFAOYSA-N 0.000 claims 1
- UXZDETPEINSEJU-UHFFFAOYSA-N 1-(2-methyl-1h-benzimidazol-4-yl)-3-(4-phenoxyphenyl)urea Chemical compound C1=CC=C2NC(C)=NC2=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 UXZDETPEINSEJU-UHFFFAOYSA-N 0.000 claims 1
- XIMUEHQPVYLCKI-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-(1h-indol-4-yl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)NC1=CC=CC2=C1C=CN2 XIMUEHQPVYLCKI-UHFFFAOYSA-N 0.000 claims 1
- DBECGFVLMGTYCA-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-(2-methyl-1,3-benzothiazol-5-yl)urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 DBECGFVLMGTYCA-UHFFFAOYSA-N 0.000 claims 1
- YWFOAHBDKVWLKQ-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-(1h-indol-4-yl)urea Chemical compound C1=C(Cl)C(C)=CC=C1NC(=O)NC1=CC=CC2=C1C=CN2 YWFOAHBDKVWLKQ-UHFFFAOYSA-N 0.000 claims 1
- LWCPXZXNPKGCRG-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-(2-methyl-1,3-benzothiazol-5-yl)urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NC1=CC=C(C)C(Cl)=C1 LWCPXZXNPKGCRG-UHFFFAOYSA-N 0.000 claims 1
- XYXMWXHATMOSND-UHFFFAOYSA-N 1-(4-bromophenyl)-3-(2-methyl-1,3-benzothiazol-5-yl)urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NC1=CC=C(Br)C=C1 XYXMWXHATMOSND-UHFFFAOYSA-N 0.000 claims 1
- GNVRVWSUVYYOOW-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-(1h-indazol-5-yl)urea Chemical compound C1=CC(F)=CC=C1NC(=O)NC1=CC=C(NN=C2)C2=C1 GNVRVWSUVYYOOW-UHFFFAOYSA-N 0.000 claims 1
- VZBDFNOZZHSPJN-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-(2-methyl-1,3-benzothiazol-5-yl)urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NC1=CC=C(F)C=C1 VZBDFNOZZHSPJN-UHFFFAOYSA-N 0.000 claims 1
- VWQINMBDIAESRC-UHFFFAOYSA-N 1-[(4-bromophenyl)methyl]-3-(1h-indol-4-yl)urea Chemical compound C1=CC(Br)=CC=C1CNC(=O)NC1=CC=CC2=C1C=CN2 VWQINMBDIAESRC-UHFFFAOYSA-N 0.000 claims 1
- GWLTVPAUAXYSAB-UHFFFAOYSA-N 1-[(4-bromophenyl)methyl]-3-(1h-indol-7-yl)urea Chemical compound C1=CC(Br)=CC=C1CNC(=O)NC1=CC=CC2=C1NC=C2 GWLTVPAUAXYSAB-UHFFFAOYSA-N 0.000 claims 1
- FHYGPSPGVNDMHW-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-3-(1h-indol-4-yl)urea Chemical compound FC(F)(F)C1=CC=C(Cl)C(NC(=O)NC=2C=3C=CNC=3C=CC=2)=C1 FHYGPSPGVNDMHW-UHFFFAOYSA-N 0.000 claims 1
- OOLGYVBJIDTCGG-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-3-(2-methyl-1,3-benzothiazol-5-yl)urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl OOLGYVBJIDTCGG-UHFFFAOYSA-N 0.000 claims 1
- QXBHRPQFPINBDW-UHFFFAOYSA-N 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-(1,1-dioxo-1-benzothiophen-6-yl)urea Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=C3S(=O)(=O)C=CC3=CC=2)=C1 QXBHRPQFPINBDW-UHFFFAOYSA-N 0.000 claims 1
- AZOGXRDZRQCPJO-UHFFFAOYSA-N 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-(1h-indazol-5-yl)urea Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=C3C=NNC3=CC=2)=C1 AZOGXRDZRQCPJO-UHFFFAOYSA-N 0.000 claims 1
- RKGLKMGUGFDKAX-UHFFFAOYSA-N 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-(1h-indol-4-yl)urea Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=3C=CNC=3C=CC=2)=C1 RKGLKMGUGFDKAX-UHFFFAOYSA-N 0.000 claims 1
- GXTDSKILHSBKND-UHFFFAOYSA-N 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-(1h-indol-7-yl)urea Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=3NC=CC=3C=CC=2)=C1 GXTDSKILHSBKND-UHFFFAOYSA-N 0.000 claims 1
- BAOJNBZUUHHLHR-UHFFFAOYSA-N 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-(2-methyl-1,3-benzothiazol-5-yl)urea Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 BAOJNBZUUHHLHR-UHFFFAOYSA-N 0.000 claims 1
- DMIBCQGHRNHFSI-UHFFFAOYSA-N 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-(2-methyl-1h-benzimidazol-4-yl)urea Chemical compound C1=CC=C2NC(C)=NC2=C1NC(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 DMIBCQGHRNHFSI-UHFFFAOYSA-N 0.000 claims 1
- XYUBWZQJSZMHLF-UHFFFAOYSA-N 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[2-(trifluoromethyl)-1h-benzimidazol-4-yl]urea Chemical compound C1=CC=C2NC(C(F)(F)F)=NC2=C1NC(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 XYUBWZQJSZMHLF-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010046494 urge incontinence Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001395031A JP2003192587A (ja) | 2001-12-26 | 2001-12-26 | 尿素誘導体 |
| PCT/EP2002/014215 WO2003055484A1 (en) | 2001-12-26 | 2002-12-13 | Urea derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005517672A JP2005517672A (ja) | 2005-06-16 |
| JP2005517672A5 true JP2005517672A5 (enExample) | 2006-02-02 |
Family
ID=19188927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001395031A Pending JP2003192587A (ja) | 2001-12-26 | 2001-12-26 | 尿素誘導体 |
| JP2003556062A Withdrawn JP2005517672A (ja) | 2001-12-26 | 2002-12-13 | 尿素誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001395031A Pending JP2003192587A (ja) | 2001-12-26 | 2001-12-26 | 尿素誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050119304A1 (enExample) |
| EP (1) | EP1465623A1 (enExample) |
| JP (2) | JP2003192587A (enExample) |
| AU (1) | AU2002367186A1 (enExample) |
| CA (1) | CA2471236A1 (enExample) |
| WO (1) | WO2003055484A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04008073A (es) * | 2002-02-20 | 2004-11-26 | Abbott Lab | Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide. |
| US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| DE60328202D1 (de) * | 2002-09-05 | 2009-08-13 | Neurosearch As | Diarylharnstoffderivate und deren verwendung als chloridkanalblocker |
| WO2004028440A2 (en) * | 2002-09-24 | 2004-04-08 | Bayer Healthcare Ag | Vr1 antagonists for the treatment of urological disorders |
| PT2017265E (pt) * | 2003-06-12 | 2011-07-29 | Abbott Lab | Compostos condensados que inibem o receptor vanilóide de subtipo 1 (vr1) |
| US7015233B2 (en) | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
| US7375126B2 (en) | 2003-06-12 | 2008-05-20 | Abbott Laboratories | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| GB0322016D0 (en) * | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
| JP4935073B2 (ja) | 2003-10-14 | 2012-05-23 | 味の素株式会社 | エーテル誘導体 |
| WO2005044802A2 (en) * | 2003-11-08 | 2005-05-19 | Bayer Healthcare Ag | Tetrahydro-quinolinylurea derivatives as vrl antagonists |
| GB0326633D0 (en) * | 2003-11-14 | 2003-12-17 | Merck Sharp & Dohme | Therapeutic agents |
| US7550499B2 (en) * | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US20080070946A1 (en) * | 2004-10-08 | 2008-03-20 | Astrazeneca Ab | Hydroxymethylbenzothiazoles Amides |
| SE0403118D0 (sv) * | 2004-12-21 | 2004-12-21 | Astrazeneca Ab | New compounds 2 |
| DE602006020327D1 (de) * | 2005-01-19 | 2011-04-07 | Bristol Myers Squibb Co | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen |
| KR20060087386A (ko) | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
| WO2007002584A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| US7700620B2 (en) * | 2005-06-27 | 2010-04-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| DE602006021306D1 (enExample) | 2005-06-27 | 2011-05-26 | Bristol Myers Squibb Co | |
| US7714002B2 (en) * | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| CN101058561B (zh) * | 2006-04-19 | 2011-01-26 | 苏州爱斯鹏药物研发有限责任公司 | 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途 |
| CA2661898A1 (en) | 2006-08-25 | 2008-02-28 | Abbott Laboratories | Indazole derivatives that inhibit trpv1 and uses thereof |
| US7960569B2 (en) * | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| CN101563318A (zh) | 2006-12-20 | 2009-10-21 | 艾博特公司 | 作为trpv1香草素受体拮抗剂用于治疗疼痛的n-(5,6,7,8-四氢萘-1-基)脲衍生物以及相关化合物 |
| WO2008128986A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Urea derivatives as glutaminyl cyclase inhibitors |
| WO2009035951A2 (en) * | 2007-09-11 | 2009-03-19 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| MX2010010262A (es) * | 2008-03-20 | 2010-12-06 | Abbott Lab | Metodos para la elaboracion de agentes para el sistema nervioso central que son antagonistas del trpv1. |
| US8362012B2 (en) | 2008-04-18 | 2013-01-29 | Daewoong Pharmaceutical Co., Ltd. | Benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof |
| EP2377850A1 (en) * | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
| KR101293384B1 (ko) | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
| CN103159686A (zh) * | 2011-12-09 | 2013-06-19 | 天津市国际生物医药联合研究院 | 一种hiv-1蛋白酶的脲类抑制剂 |
| EP2788345B1 (en) * | 2011-12-09 | 2020-06-10 | Chiesi Farmaceutici S.p.A. | Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract |
| WO2020252240A1 (en) * | 2019-06-14 | 2020-12-17 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| KR102334947B1 (ko) * | 2020-04-22 | 2021-12-06 | 주식회사 제이맥켐 | Trpv1 길항제로서 벤즈이미다졸론계 시남아마이드 유도체 및 이를 유효성분으로 함유하는 통증의 치료 또는 예방용 약학적 조성물 |
| CN111704714B (zh) * | 2020-07-01 | 2023-08-04 | 浙江大学 | 一种苯并五元、六元环(硫)脲催化剂及其在开环聚合中的应用 |
| US12152018B2 (en) | 2021-01-08 | 2024-11-26 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with STING activity |
| DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
| CN114805236B (zh) * | 2022-06-06 | 2024-02-23 | 苏州大学 | 一种苯并恶唑衍生物及其制备方法和应用 |
| CZ310092B6 (cs) * | 2023-01-22 | 2024-07-31 | Univerzita Hradec Králové | Heterocyklická sloučenina pro inhibici růstu maligních tumorů |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3711610A (en) * | 1971-06-01 | 1973-01-16 | Sterling Drug Inc | Anticoccidiosis method and compositions involving indazolylphenylureas and indazolylphenylthioureas |
| US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| US6294694B1 (en) * | 1999-06-04 | 2001-09-25 | Wisconsin Alumni Research Foundation | Matrix metalloproteinase inhibitors and method of using same |
| US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| WO2001068652A1 (en) * | 2000-03-17 | 2001-09-20 | Novo Nordisk A/S | Condensed imidazoles as histamine h3 receptor ligands |
| EP1303483B1 (en) * | 2000-08-21 | 2008-04-23 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| GB0110901D0 (en) * | 2001-05-02 | 2001-06-27 | Smithkline Beecham Plc | Novel Compounds |
-
2001
- 2001-12-26 JP JP2001395031A patent/JP2003192587A/ja active Pending
-
2002
- 2002-12-13 EP EP02805752A patent/EP1465623A1/en not_active Withdrawn
- 2002-12-13 WO PCT/EP2002/014215 patent/WO2003055484A1/en not_active Ceased
- 2002-12-13 AU AU2002367186A patent/AU2002367186A1/en not_active Abandoned
- 2002-12-13 JP JP2003556062A patent/JP2005517672A/ja not_active Withdrawn
- 2002-12-13 CA CA002471236A patent/CA2471236A1/en not_active Abandoned
- 2002-12-13 US US10/499,788 patent/US20050119304A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005517672A5 (enExample) | ||
| JP4592819B2 (ja) | 抗寄生虫剤 | |
| RU2331635C2 (ru) | Производные гидрокси-тетрагидро-нафталенилмочевины | |
| JP2009505962A5 (enExample) | ||
| RU2420522C2 (ru) | Новый класс ингибиторов гистондеацетилаз | |
| RU2006131304A (ru) | Производные имидазо[1,2-c]пиримидинилуксусной кислоты | |
| JP2004517925A5 (enExample) | ||
| JP2004523581A5 (enExample) | ||
| JP2009514954A (ja) | Ｔｒｐｖ３機能を変調するための化合物 | |
| JP2005522438A5 (enExample) | ||
| RU2005136655A (ru) | Производные пиримидина, пригодные для лечения болезней, опосредованных сrth2 | |
| HRP980025A2 (en) | Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agents and medicaments containing them | |
| CA2508618A1 (en) | Tetrahydro-naphthalene derivatives | |
| JP2009532438A5 (enExample) | ||
| JP2011519832A5 (enExample) | ||
| BRPI0712938A2 (pt) | mÉtodo para modular excrescÊncia de neurito pelo uso de um antagonista de receptor de galanina-3 | |
| CA2508845A1 (en) | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | |
| US9714219B2 (en) | Sulfonylaminobenzamide compounds | |
| TW200820906A (en) | Organic compounds | |
| RU2294640C2 (ru) | Применение аминоацетонитрильных соединений в качестве действующего вещества для борьбы с эндопаразитами у теплокровных продуктивного скота и домашних животных, композиция для борьбы с эндопаразитами у теплокровных продуктивного скота и домашних животных и способ борьбы с эндопаразитами у теплокровных продуктивного скота и домашних животных | |
| JP2008506787A (ja) | 動物においてミオスタチン活性を調節または阻害して赤身組織の成長増加を導くａｌｋ５インヒビターの使用 | |
| JP2011524362A5 (enExample) | ||
| JP5685364B2 (ja) | トリアゾール化合物による炎症性疾患の処置 | |
| WO2002045750A1 (en) | Combination drugs | |
| JP2020524660A5 (enExample) |